133 completed, 65 recruiting, 52 unknown, 23 not yet recruiting. 65 Not applicable, 63 Phase 3, 57 Phase 2, 36 Phase 4, 30 Phase 1.
Follow Graves Disease: new trials by email Literature Review of Graves Disease trials Research Report on Graves Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Not yet recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 219 | 2027-07-01 | 2026-06-04 |
| Impact of Restrictive Diets on Inflammation and Quality of Life in Autoimmune Thyroiditis Gluten-free, casein-free, low-glycemic-index diet - Thyroid Autoimmune Disease, Hashimoto's Thyroiditis | Not applicable | Not yet recruiting | University of Barcelona | 60 | 2027-01-01 | 2026-10-19 |
| Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) REGN24493, Placebo - Graves' Disease | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 45 | 2026-11-02 | 2026-10-06 |
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease Glandy HYPER (AI-based monitoring software), Methimazole - Hyperthyroidism, Graves Disease | Not applicable | Not yet recruiting | THYROSCOPE INC. | 30 | 2026-10-20 | 2026-10-05 |
| Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED Betamethasone - Thyroid Eye Disease | Not applicable | Not yet recruiting | Assiut University | 54 | 2026-10-10 | 2026-10-08 |
| Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study MHB018A, MHB018A placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 84 | 2026-09-28 | 2026-10-14 |
| Treatment of Chronic Thyroid Eye Disease With MHB018A MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 135 | 2026-09-24 | 2026-10-14 |
| Thyroid Disorders in Pediatric Autoimmune Hepatitis Thyroid Disease, Autoimmune Hepatitis | Not yet recruiting | Assiut University | 32 | 2026-09-15 | 2026-09-22 | |
| An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease | Phase 4 | Not yet recruiting | Viridian Therapeutics, Inc. | 30 | 2026-09-01 | 2026-09-21 |
| Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED | Not yet recruiting | University of Copenhagen | 430 | 2026-09-01 | 2026-09-10 | |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy | Phase 3 | Recruiting | Sling Therapeutics, Inc. | 130 | 2026-08-04 | 2026-10-20 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 60 | 2026-08-01 | 2026-07-23 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 117 | 2026-08-01 | 2026-07-23 |
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Teprotumumab N01, Methylprednisolone - Thyroid Eye Disease | Phase 4 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 92 | 2026-07-30 | 2026-08-13 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-22 |
| Telehealth Music Therapy for Adults With Endocrine Disorder and Depression Telehealth Resource Oriented Music Therapy - Type 1 Diabetes, Hashimoto Disease | Not applicable | Recruiting | Appalachian State University | 10 | 2026-07-16 | 2026-07-30 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-21 |
Showing 20 of 320. Sign in to see all of them.
Graves Ophthalmopathy (197) · Hyperthyroidism (38) · Thyroid Diseases (22) · Exophthalmos (17) · Hashimoto Disease (17) · Autoimmune Diseases (15) · Eye Diseases (12) · Endocrine System Diseases (9) · Thyroid Neoplasms (8) · Goiter (7) · Celiac Disease (5) · Diabetes Mellitus, Type 1 (5) · Multiple Sclerosis (5) · Thyrotoxicosis (5)
Immune System Diseases (317) · Orbital Diseases (316) · Goiter (313) · Endocrine System Diseases (311) · Eye Diseases (308) · Autoimmune Diseases (305) · Exophthalmos (303) · Thyroid Diseases (298) · Hyperthyroidism (282) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (203) · Genetic Diseases, Inborn (202) · Eye Diseases, Hereditary (194) · Pathological Conditions, Signs and Symptoms (25) · Thyroiditis (18)
Methylprednisolone (22) · Methimazole (21) · teprotumumab (15) · Selenium (6) · Sodium Chloride (6) · Atorvastatin (5) · Methylprednisolone Hemisuccinate (5) · Propylthiouracil (5) · Saline Solution (5) · tocilizumab (5) · Glucocorticoids (4) · Iodine-131 (4) · Prednisone (4) · Rituximab (4) · Sirolimus (4)
Amgen (14) · Sun Yat-sen University (14) · University of Pisa (12) · Immunovant Sciences GmbH (9) · Viridian Therapeutics, Inc. (9) · Shanghai Changzheng Hospital (7) · Assiut University (6) · Innovent Biologics (Suzhou) Co. Ltd. (6) · Minghui Pharmaceutical (Hangzhou) Ltd (6) · National Taiwan University Hospital (6) · Mayo Clinic (4) · Medical University of Warsaw (4) · THYROSCOPE INC. (4) · The University of Hong Kong (4) · Vastra Gotaland Region (4)
United States (85) · China (70) · Italy (33) · Spain (30) · Germany (27) · United Kingdom (27) · Poland (21) · France (20) · Australia (16) · Canada (12) · Denmark (11) · Hungary (10) · Taiwan (10) · Sweden (9) · Belgium (8)
Dan Liang (3) · Dan Liang, MD (3) · Fangsen Xiao, MD (2) · Hung Hin, Brian Lang, MBBS(Hons) (2) · Mohsen B Kashkouli, MD (2) · Yunwei Wei (2) · Aase K Rasmussen, DMSc (1) · Ahmed Abdelal, MD (1)
PMID 27797318, PMID 18299459, PMID 19850691, PMID 33768488, PMID 41066062, PMID 10427152, PMID 10634372, PMID 10873993, PMID 11129808, PMID 11442004, PMID 11535445, PMID 12050214, PMID 12225640, PMID 12541136, PMID 12608932, PMID 12848966, PMID 14398978, PMID 15068625, PMID 15588952, PMID 16140250, PMID 16286624, PMID 16704685, PMID 16864757, PMID 17057811, PMID 17299648, PMID 17389702, PMID 1802923, PMID 18242338, PMID 18366712, PMID 18946743, PMID 19022998, PMID 19139595, PMID 19643971, PMID 19865824, PMID 20126486, PMID 20181974, PMID 20305505, PMID 20739336, PMID 21175612, PMID 21215658, PMID 21730841, PMID 21852080, PMID 21915479, PMID 21964170, PMID 22124787, PMID 22219499, PMID 22287122, PMID 22298862, PMID 22442048, PMID 22443978
2023 (6), 2025 (6), 2015 (2), 2017 (2), 2004 (1), 2005 (1), 2009 (1), 2014 (1), R01DK042822 (1), R01DK077814 (1), UL1RR024150 (1), UL1TR000005 (1)